Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Status Recruiting

Clinical Trial Summary

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. - The name of the study drug involved in this study is: - Zafirlukast

Clinical Trial Description

This is a single-arm Simon two-stage phase 2 clinical trial to determine whether zafirlukast reduces the tumor marker CA-125 as well the tendency to form blood clots in tumor marker-only relapsed ovarian cancer. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. - The name of the study drug involved in this study is: - Zafirlukast Eligible participants will receive study treatment for up to 1 year and will be followed for up to one year following treatment. It is expected that about 30 people will take part in this research study. The U.S. Food and Drug Administration (FDA) has not approved zafirlukast for this specific disease but it has been approved for other uses. Zafirlukast is currently approved to be used for the treatment of asthma. It has been recently learned that Zakfirlukast demonstrates anti-tumor activity in laboratory studies of ovarian cancer. This means that these results were not found in humans. The National Institutes of Health are supporting this research study by providing funding ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04339140
Study type	Interventional
Source	Beth Israel Deaconess Medical Center
Contact	Rushad Patell, MD
Phone	617-667-2139
Email	rpatell@bidmc.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	June 24, 2020
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Withdrawn	`NCT05201001` - APX005M in Patients With Recurrent Ovarian Cancer	Phase 2
Completed	`NCT02963831` - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies	Phase 1/Phase 2
Not yet recruiting	`NCT06376253` - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers	Phase 1
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05156892` - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer	Phase 1
Suspended	`NCT02432378` - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines	Phase 1/Phase 2
Recruiting	`NCT04533763` - Living WELL: A Web-Based Program for Ovarian Cancer Survivors	N/A
Active, not recruiting	`NCT03371693` - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer	Phase 3
Withdrawn	`NCT03032614` - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients	Phase 2
Completed	`NCT02019524` - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients	Phase 1
Completed	`NCT01936363` - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer	Phase 2
Terminated	`NCT00788125` - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Terminated	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Terminated	`NCT03146663` - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer	Phase 2